Saenko V.S.
Pesegov S.V.
Frolova E.A.
Institute of Urology and Male Reproductive Health named of FGAOU VO of I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia, Moscow, Russia.
Role of drinking and dietary factors in effective dissolution therapy and recurrence prevention of uric acid kidney stones
Текст визуальный электронный
Urologiia (Moscow, Russia : 1999)
№ 2 С. 113-118
2019
drinking and dietary factors of effective dissolution therapy
recurrence prevention
uric acid kidney stones
Статья
Citric Acid metabolism D02.241.081.901.434.249
Citric Acid urine D02.241.081.901.434.249
Лимонная кислота метаболизм D02.241.081.901.434.249
Лимонная кислота моча D02.241.081.901.434.249
Drinking G07.203.650.283.249 G10.261.330.249
Питье G07.203.650.283.249 G10.261.330.249
Humans B01.050.150.900.649.313.988.400.112.400.400
Человек B01.050.150.900.649.313.988.400.112.400.400
Hydrogen-Ion Concentration G02.300
Водородных ионов концентрация G02.300
Kidney Calculi chemistry C12.050.351.968.419.600.500 C12.050.351.968.967.249.500 C12.050.351.968.967.500.503 C12.200.777.419.600.500 C12.200.777.967.249.500 C12.200.777.967.500.503 C12.950.419.600.500 C12.950.967.249.500 C12.950.967.500.503 C23.300.175.850.550
Kidney Calculi diet therapy C12.050.351.968.419.600.500 C12.050.351.968.967.249.500 C12.050.351.968.967.500.503 C12.200.777.419.600.500 C12.200.777.967.249.500 C12.200.777.967.500.503 C12.950.419.600.500 C12.950.967.249.500 C12.950.967.500.503 C23.300.175.850.550
Kidney Calculi prevention & control C12.050.351.968.419.600.500 C12.050.351.968.967.249.500 C12.050.351.968.967.500.503 C12.200.777.419.600.500 C12.200.777.967.249.500 C12.200.777.967.500.503 C12.950.419.600.500 C12.950.967.249.500 C12.950.967.500.503 C23.300.175.850.550
Почечнокаменная болезнь химия C12.050.351.968.419.600.500 C12.050.351.968.967.249.500 C12.050.351.968.967.500.503 C12.200.777.419.600.500 C12.200.777.967.249.500 C12.200.777.967.500.503 C12.950.419.600.500 C12.950.967.249.500 C12.950.967.500.503 C23.300.175.850.550
Почечнокаменная болезнь диетотерапия C12.050.351.968.419.600.500 C12.050.351.968.967.249.500 C12.050.351.968.967.500.503 C12.200.777.419.600.500 C12.200.777.967.249.500 C12.200.777.967.500.503 C12.950.419.600.500 C12.950.967.249.500 C12.950.967.500.503 C23.300.175.850.550
Почечнокаменная болезнь профилактика и контроль C12.050.351.968.419.600.500 C12.050.351.968.967.249.500 C12.050.351.968.967.500.503 C12.200.777.419.600.500 C12.200.777.967.249.500 C12.200.777.967.500.503 C12.950.419.600.500 C12.950.967.249.500 C12.950.967.500.503 C23.300.175.850.550
Mineral Waters therapeutic use D01.045.250.875.600 D01.248.497.158.459.650.600 D01.650.550.925.600
Минеральные воды терапевтическое применение D01.045.250.875.600 D01.248.497.158.459.650.600 D01.650.550.925.600
Recurrence C23.550.291.937
Рецидив C23.550.291.937
Risk Factors E05.318.740.600.800.725 N05.715.350.200.700 N05.715.360.750.625.700.700 N06.850.490.625.750 N06.850.520.830.600.800.725
Факторы риска E05.318.740.600.800.725 N05.715.350.200.700 N05.715.360.750.625.700.700 N06.850.490.625.750 N06.850.520.830.600.800.725
Secondary Prevention E02.897 N02.421.726.825 N06.850.780.750
Профилактика вторичная E02.897 N02.421.726.825 N06.850.780.750
Solubility G02.805
Растворимость G02.805
Uric Acid chemistry D03.132.960.877 D03.633.100.759.758.824.877
Uric Acid metabolism D03.132.960.877 D03.633.100.759.758.824.877
Мочевая кислота химия D03.132.960.877 D03.633.100.759.758.824.877
Мочевая кислота метаболизм D03.132.960.877 D03.633.100.759.758.824.877
Journal Article V02.600
Журнальная статья V02.600
The use of alkaline mineral waters leads to alkalization of urine and an increase in level of urinary citrate, which represent important factor inhibiting the formation of urinary stones. Combination of alkaline mineral waters with citrates facilitates the achievement of target urine pH level not only during dissolution therapy, but also during recurrence prevention. Alkalization of urine and reducing of the influence of alimentary factor dont preclude drug therapy. Patients should be counselled about complex strategies aimed to modifiable risk factors for urinary stone disease.